Lyme disease is diagnosed through a combination of clinical evaluation and blood testing, but the approach depends heavily on timing. If you have the characteristic expanding rash, a doctor can diagnose Lyme disease on sight without any lab work. If the rash is absent or you’re past the early stage, diagnosis relies on a two-step blood test that detects antibodies your immune system produces against the bacteria.
The Rash Can Be Enough on Its Own
The expanding red rash known as erythema migrans is the single most reliable sign of early Lyme disease, and when a doctor sees it, no blood test is needed to start treatment. The classic “bull’s-eye” pattern with concentric rings gets a lot of attention, but it’s actually not the most common presentation. Most Lyme rashes appear as a solid, uniformly red patch that expands over days. The bull’s-eye version is the only pattern considered unmistakable for Lyme, but any expanding red patch after a tick bite in an area where Lyme is common warrants treatment.
Here’s the catch: only about 70 to 80 percent of people with Lyme disease ever develop a visible rash. Some never notice it, especially if it appears on the scalp or back. And blood tests are often negative during this early window because your body hasn’t produced enough antibodies yet. This creates a diagnostic gap where the rash is the only reliable marker, and missing it can delay diagnosis by weeks.
How the Two-Tier Blood Test Works
When blood testing is needed, the CDC recommends a two-step process. Both steps can be run from the same blood draw.
The first step is a screening test called an enzyme immunoassay (EIA). If this comes back negative, testing stops there and the result is considered negative. If it’s positive or borderline, the lab runs a second, more specific test to confirm. In the standard version of this protocol, the second test is a Western blot, which looks for antibodies that react to specific proteins from the Lyme bacteria. For early infection, the Western blot needs to show at least 2 out of 3 specific antibody bands to count as positive. For later infection, the bar is higher: at least 5 out of 10 bands must be present.
The overall result is only considered positive when both steps come back positive. This two-tier approach has a specificity of 99 percent or greater, meaning false positives are rare. The tradeoff is sensitivity, particularly in the early weeks of infection.
Why Timing Matters So Much
The biggest limitation of blood testing for Lyme disease is that antibodies take time to develop. During the first few weeks after a tick bite, when you might have a rash and flu-like symptoms, tests frequently come back negative even though you’re infected.
In early localized infection with a single rash, the standard two-tier test catches only about 14 to 40 percent of cases. If the infection has started to spread and you have multiple rashes, sensitivity climbs to around 65 percent. By the time four to six weeks have passed, most FDA-cleared tests perform well. And by the late stage, when Lyme has progressed to joint inflammation or neurological symptoms, sensitivity reaches 96 to 100 percent.
This is exactly why doctors are told not to rely on blood tests when someone walks in with an expanding rash. Testing too early produces misleading negatives. If your doctor suspects early Lyme based on symptoms and exposure history, treatment typically starts before waiting for test results.
Newer Testing Options
The CDC now also accepts a modified two-tier protocol that replaces the Western blot in the second step with a different type of immunoassay. Instead of the traditional screening test followed by a Western blot, two immunoassays are run in sequence. This approach has shown meaningfully better sensitivity in early disease: 61 to 74 percent versus 29 to 48 percent for the standard protocol in early localized infection. In early disseminated disease, the modified approach reached 100 percent sensitivity compared to just 40 percent with traditional two-tier testing. Specificity remained equally high at 99.5 percent.
These newer tests must be FDA-cleared specifically for use together. Not all labs have adopted them yet, but they represent a significant improvement for catching Lyme disease earlier.
Testing for Specific Complications
For certain presentations of Lyme disease, additional testing beyond standard blood work can help. When Lyme arthritis is suspected, PCR testing on joint fluid can detect bacterial DNA directly rather than relying on antibodies. This is particularly useful because patients with Lyme arthritis are almost always antibody-positive on blood tests anyway, but PCR can provide additional confirmation and rule out other causes of joint swelling.
For suspected Lyme-related nervous system involvement, doctors may test spinal fluid alongside blood to look for antibodies being produced within the central nervous system. Sensitivity in early neurological Lyme ranges from 80 to 100 percent depending on the population.
Co-infections From the Same Tick Bite
The same blacklegged tick that carries Lyme bacteria can also transmit other pathogens, and roughly 4 to 5 percent of Lyme patients in areas where the disease is common are co-infected with either anaplasmosis or babesiosis. These infections cause overlapping symptoms like fever, fatigue, and muscle aches, but they require different treatments.
If your symptoms seem more severe than typical early Lyme, or if you have high fevers and abnormal blood counts that aren’t characteristic of Lyme alone, your doctor may order a broader tick-borne disease panel. These panels test for multiple pathogens at once. For acute anaplasmosis, babesiosis, and related infections, PCR-based molecular tests perform best within the first seven days of symptoms, while antibody-based tests take longer to turn positive.
Conditions That Mimic Lyme Disease
Several conditions produce symptoms or lab results that overlap with Lyme disease, which is one reason the two-tier testing protocol exists. The rash itself can be confused with cellulitis, contact dermatitis, or a skin condition called granuloma annulare. Joint symptoms from Lyme can look like rheumatoid arthritis or gout. Neurological Lyme can resemble other causes of nerve inflammation or memory problems.
Adding to the complexity, ehrlichial infection (another tick-borne illness) can trigger a false-positive result on the early antibody portion of Western blot testing. This is another reason the full two-step protocol matters: the confirmation step filters out most of these cross-reactions.
Reinfection is also possible. Antibodies from a previous Lyme infection don’t protect you from future tick bites carrying the bacteria, and a new infection can easily be mistaken for a relapse of the original one. If you’ve had Lyme before and develop new symptoms after another possible tick exposure, your doctor will need to consider both possibilities.